Abstract
Background Artemisinin partial resistance, mediated by mutations in the Plasmodium falciparum Kelch13 protein (K13), rapidly spread in South-East Asia (SEA), undermining antimalarial efficacies of artemisinin-based combination therapies (ACT). Validated K13 mutations have recently arisen in Africa, but rates of increase are not well characterized.
Methods We investigated K13 mutation prevalence at 16 sites in Uganda (2016-2022, 6586 samples), and five sites in SEA (2003-2018, 5465 samples) by calculating selection coefficients using Bayesian mixed-effect linear models. We then tested whether SEA K13 mutation prevalence could have been forecast accurately using up to the first five years of available data and forecast future K13 mutation prevalence in Uganda.
Findings The selection coefficient for the prevalence of relevant K13 mutations (441L, 469F/Y, 561H, 675V) was estimated at s=0·383 (95% CrI: 0·247 - 0·528) per year, a 38% relative prevalence increase. Selection coefficients across Uganda were s=0·968 (0·463 - 1·569) for 441L, s=0·153 (- 0·445 - 0·727) for 469F, s=0·222 (−0·011 - 0·398) for 469Y, and s=0·152 (−0·023 - 0·312) for 675V. In SEA, the selection coefficient was s=−0·005 (−0·852 - 0·814) for 539T, s=0·574 (−0·092 - 1·201) for 580Y, and s=0·308 (0·089 - 0·536) for all validated K13 mutations. Forecast prevalences for Uganda assuming constant selection neared fixation (>95% prevalence) within a decade (2028-2033) for combined K13 mutations.
Interpretation The selection of K13 mutations in Uganda was at a comparable rate to that observed in SEA, suggesting K13 mutations may continue to increase quickly in Uganda.
Funding NIH R01AI156267, R01AI075045, and R01AI089674.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CMS, OJW, LO, and JAB are funded by R01AI156267. VA, TK SG, MDC, and PJR are funded by AI075045 and AI089674. OJW is supported by an Eric and Wendy Schmidt AI in Science Postdoctoral Fellowship, a Schmidt Futures program. LO is funded by the UK Royal Society, UK Medical Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The longitudinal K13 mutation prevalence data from Uganda used for this study were published by Conrad et al. NEJM (2023) https://www.nejm.org/doi/full/10.1056/NEJMoa2211803. The K13 mutation prevelance data from South-East Asia were obtained from the MalariaGen Pf7 dataset. https://www.malariagen.net/apps/pf7/samples
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/bailey-lab/selmar.
